Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data Maze Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Revenue
168
Research and development
83.5
108
General and administrative
26.4
34.5
Operating expenses
110
143
Operating income
57.6
-143
Pre-tax income
53.4
-131
Income tax
1.17
0
Net income
52.2
-131
EBITDA
60.9
-140
EPS, basic
1.42
-3.05
EPS, diluted
1.25
-3.05
Shares, basic (weighted)
2.4
43
Shares, diluted (weighted)
2.73
43
Balance sheet
FY2025
FY2025
Cash and equivalents
197
189
Short-term investments
153
Other current assets
4.86
7.8
Total current assets
202
350
Property, plant and equipment
6.67
5.04
Lease right-of-use assets
23.3
20.1
Long-term investments
18.1
Other non-current assets
7.87
3.05
Total assets
241
397
Accounts payable
1.94
1.79
Accrued liabilities
8.08
10.9
Total current liabilities
20.7
22.6
Lease liabilities
22
18.5
Other non-current liabilities
0.97
1.09
Total liabilities
43.6
42.2
Paid-in capital
47.2
844
Retained earnings
-358
-490
Shareholders' equity
-311
355
Total equity
-311
355
Total liabilities and equity
241
397
Shares outstanding
2.45
49.3
Cash flow statement
FY2025
FY2025
Net income
52.2
-131
Depreciation and amortization
3.3
2.4
Stock-based compensation
9.65
16.4
Change in payables
-0.2
-0.03
Cash from operations
76
-112
Capital expenditures
-1.15
-0.79
Purchases of investments
-188
Sales and maturities of investments
17.5
Cash from investing
-1.15
-171
Stock issued
0.73
5.56
Cash from financing
92.8
275
Net change in cash
168
-7.57
Free cash flow
74.8
-113
Income taxes paid
1.23
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2026; growth uses fiscal years. Valuation uses the share price of $35.45 on November 10, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-35.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-29.6%
Net income / average total assets.
Return on invested capital (ROIC)
-41.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Operating income growth, 1y
-348.1%
Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y
-330.8%
EBITDA vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
-351.0%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
-344.0%
EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
-247.4%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
-250.7%
Free cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
65.1%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
1,474.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
14.1x
Current assets / current liabilities.
Quick ratio
13.8x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
13.8x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.09x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
7.6%
Total debt / total assets.
Liabilities / assets
16.2%
Total liabilities / total assets.
Net debt
-$350.5M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.89
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.89
Cash from operations / diluted weighted shares.
Book value per share
$7.59
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
4.60x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.60x
Market cap / tangible book value, when positive.
FCF yield
-5.9%
Free cash flow / market cap.
Earnings yield
-7.7%
Net income / market cap (the inverse of P/E).
Was Maze Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $131.1M.
How much free cash flow did Maze Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $111.9M minus capital expenditures of $794.0K left free cash flow of -$112.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.